RLYB
Rallybio CorpCompany Information
- Company Name
- Rallybio Corp
- CIK
- CIK0001739410
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- RLYB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RLYB
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-19
- Last sale
- 2026-02-23
- Shares purchased (TTM)
- 46,401
- Shares sold (TTM)
- 789
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,764,393
- Shares outstanding
- 5,699,111
- Ownership
- 83.60%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 3.83%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 93 | 41 | 31 | 32 | 9 | 15 | 14 | 25 | 17 | 19 | 24 | 19 | ||||||
| Marketable Securities Current | 0 | 5 | 23 | 27 | 36 | 40 | 52 | 50 | 72 | 75 | 85 | 102 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 7 | 7 | 7 | 5 | 3 | 2 | 3 | 3 | 4 | 5 | 11 | ||||||
| Assets Current | 97 | 53 | 61 | 67 | 50 | 57 | 68 | 78 | 91 | 99 | 115 | 132 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | - | - | - | - | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Assets | 98 | 54 | 62 | 68 | 51 | 58 | 68 | 79 | 92 | 99 | 116 | 133 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | ||||||
| Accrued Liabilities Current | 1 | 3 | 4 | 4 | 4 | 3 | 5 | 6 | 10 | 9 | 8 | 9 | ||||||
| Accrued Income Taxes Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | 0 | - | ||||||
| Liabilities Current | 4 | 4 | 4 | 5 | 5 | 4 | 6 | 8 | 12 | 10 | 9 | 9 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 0 | - | ||||||
| Liabilities | 4 | 4 | 4 | 5 | 5 | 4 | 6 | 8 | 12 | 10 | 9 | 10 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 361 | 361 | 360 | 359 | 358 | 356 | 355 | 353 | 351 | 343 | 341 | 339 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -267 | -310 | -302 | -296 | -312 | -302 | -293 | -282 | -271 | -254 | -235 | -215 | ||||||
| Stockholders Equity | 94 | 50 | 58 | 63 | 46 | 54 | 62 | 71 | 80 | 89 | 106 | 124 | ||||||
| Liabilities And Stockholders Equity | 98 | 54 | 62 | 68 | 51 | 58 | 68 | 79 | 92 | 99 | 116 | 133 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Shares Outstanding | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRallybio Corp (RLYB) — SEC Financial Statements & Analysis
Rallybio Corp (RLYB) is a pharmaceutical preparations company, incorporated in DE. Rallybio Corp trades on Nasdaq as: RLYB. Rallybio Corp (RLYB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Rallybio Corp carries a market cap of $91.19M, a P/E ratio of 2.00x, a P/B ratio of 0.96x, a P/S ratio of 141.15x, an enterprise value of $-1.66M, and an EV/EBITDA multiple of 0.06x. On profitability, it posts an operating margin of -4291.49%, a net margin of 7051.24%, a Return on Equity (ROE) of 64.86%, a Return on Assets (ROA) of 61.12%, and a Return on Invested Capital (ROIC) of -141.07%. Per share, it reports EPS of $7.99, diluted EPS of $7.86, free cash flow per share of $4.69, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -15.11% year-over-year, net income growth of -209.36% year-over-year, and EPS growth of -207.56% year-over-year. On the balance sheet, it maintains a current ratio of 27.26x, a quick ratio of 26.03x, working capital of $93.69M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, free cash flow of $26.71M (TTM), and net debt of $-92.85M. Figures sourced from SEC EDGAR.
- Market Cap
- $91.19M
- P/E TTM
- 2.00x
- EPS TTM
- $7.99
- P/B TTM
- 0.96x
- ROE TTM
- 64.86%
- ROA TTM
- 61.12%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $26.71M
- Net Revenue TTM Growth 1Y
- -15.11%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Rallybio Corp in?
Rallybio Corp (RLYB) operates in the Pharmaceutical Preparations industry.
What exchange does RLYB trade on?
Rallybio Corp (RLYB) trades on the Nasdaq.
Where is Rallybio Corp incorporated?
Rallybio Corp is incorporated in DE.
When was Rallybio Corp (RLYB)'s most recent SEC filing?
Rallybio Corp (RLYB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is RLYB's market cap?
Rallybio Corp (RLYB) has a market capitalization of $91.19M as of 2026-06-30.
What is RLYB's P/E ratio?
Rallybio Corp (RLYB)'s trailing twelve month P/E ratio is 2.00x as of 2026-06-30.
What is RLYB's EPS (earnings per share)?
Rallybio Corp (RLYB)'s trailing twelve month EPS is $7.99 as of 2026-06-30.
What is RLYB's ROE (return on equity)?
Rallybio Corp (RLYB)'s trailing twelve month Return on Equity (ROE) is 64.86% as of 2026-06-30.
What is RLYB's ROA (return on assets)?
Rallybio Corp (RLYB)'s trailing twelve month Return on Assets (ROA) is 61.12% as of 2026-06-30.
What is RLYB's ROIC (return on invested capital)?
Rallybio Corp (RLYB)'s trailing twelve month Return on Invested Capital (ROIC) is -141.07% as of 2026-06-30.
What is RLYB's EV/EBITDA?
Rallybio Corp (RLYB)'s trailing twelve month EV/EBITDA is 0.06x as of 2026-06-30.